EcoDrugPlus

Integrin Beta-3-Like

Ensembl ID : ENSOMEG00000004171
Gene Symbol: LOC112154448
3 Cross references
194 Possible Orthologues:

Integrin Beta-3-Like

Ensembl ID : ENSOMEG00000022546
Gene Symbol: LOC112146702
3 Cross references
201 Possible Orthologues:

Integrin Subunit Alpha 4

Ensembl ID : ENSOMEG00000015047
Gene Symbol: ITGA4
1 Cross references
225 Possible Orthologues:

Integrin Subunit Alpha V

Ensembl ID : ENSOMEG00000006663
Gene Symbol: ITGAV
3 Cross references
237 Possible Orthologues:

Integrin Subunit Beta 1

Ensembl ID : ENSOMEG00000020566
Gene Symbol: ITGB1
3 Cross references
214 Possible Orthologues:

Integrin Subunit Beta 5

Ensembl ID : ENSOMEG00000021432
Gene Symbol: ITGB5
3 Cross references
205 Possible Orthologues:

Integrin Subunit Beta 6

Ensembl ID : ENSOMEG00000014664
Gene Symbol: ITGB6
1 Cross references
205 Possible Orthologues:

Integrin Subunit Beta 8

Ensembl ID : ENSOMEG00000015733
Gene Symbol: ITGB8
2 Cross references
201 Possible Orthologues:

Interleukin 1 Receptor Associated Kinase 4

Ensembl ID : ENSOMEG00000009757
Gene Symbol: IRAK4
3 Cross references
201 Possible Orthologues:

Interleukin-1 Receptor-Associated Kinase 4

Ensembl ID : ENSOMEG00000008582
Gene Symbol: IRAK4
1 Cross references
201 Possible Orthologues:

Interleukin-8-Like

Ensembl ID : ENSOMEG00000013850
Gene Symbol: LOC112156986
3 Cross references
183 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSOMEG00000011210
Gene Symbol: IDH1
3 Cross references
234 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).